Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
about
Targeting angiogenesis in gynecologic cancersGrowth factor and signaling pathways and their relevance to prostate cancer therapeuticsAnti-angiogenesis in prostate cancer: knocked down but not outApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsKidney cancerProfile of trebananib (AMG386) and its potential in the treatment of ovarian cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyAngiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectivesDrugs derived from phage display: from candidate identification to clinical practiceResistance and escape from antiangiogenesis therapy: clinical implications and future strategiesAdaptation to antiangiogenic therapy in neurological tumorsA phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaA novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.Combinatorial peptide libraries: mining for cell-binding peptides.Peptibodies: A flexible alternative format to antibodies.Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.Angiogenic factors in sepsis: are we ready for the new therapeutic era?Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancerActive immunotherapy induces antibody responses that target tumor angiogenesis.Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapyThe role of angiopoietins as potential therapeutic targets in renal cell carcinoma.Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment.A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis.Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.Imaging in clinical trials.Present and future evolution of advanced breast cancer therapy.Antibody-based therapeutics to watch in 2011.Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmA new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaquesA phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.Antiangiogenic therapy for breast cancerAnti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Therapeutic advances in women's cancersUnique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression.Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.
P2860
Q26824766-745F5ED8-C27F-4E1A-9B2C-24A4CABC931FQ26827975-9381AD37-1228-418E-A24C-BAA888612704Q26851183-A755BF63-F0AF-4E16-A95E-CD0B971A3DBFQ26852287-3C1B331A-EA9A-4BAF-9F00-BE14AAA0A9EDQ26866709-885E7164-F243-4C33-A9F0-120D27E38D69Q26991997-6A7F5C55-CE84-4820-9DBA-A29E51AF4A2DQ26993238-493EB737-6CB8-44BB-99F4-49C4DA6F576CQ27006707-5DB57F92-A040-47C0-80E9-F64EDCD87BE5Q27007101-4B6A737E-A5E8-4AC4-A72D-955A4DA718BEQ27016629-724C6E9B-0259-4AE3-8DF1-4838C494E808Q28082908-0AF08BF7-5219-4426-96A1-44334E98547DQ28304566-0C2B8634-D656-4D63-AE6D-1B4D35225E0BQ31110832-59D384E4-001C-46F5-86D3-AC883EAB2BDAQ31144876-5E48D8F6-389D-477A-9F29-F94A0B3C63A2Q33402480-36EF31F0-F89E-4A3F-9E00-E14DDCB95922Q33520512-DA3FC26C-F97B-4A85-9500-BE4A065F252BQ33732486-A619AE5F-9BC0-49F4-8E8D-B7AD118C8A1EQ33751368-19877801-F938-44B4-8B90-C7A5C526B556Q33760079-D3A4AD5C-2D63-4000-9485-141DD0F08864Q33772446-7595D9B8-E9BB-4C58-8087-2E646D8AE403Q33779567-FCB88F90-46DE-4D04-9A86-CFE629366797Q33912405-FE3A611F-6AB5-470D-917E-762DADB8EDC9Q33978086-BB98A70D-6497-4AEF-846B-4F15881D6C79Q33996024-689C4398-607C-4C30-B20F-C8E2369DE831Q34208140-8BB78F8C-3E51-4DDD-9370-6C813E370688Q34256382-6D8330B9-A14E-4A93-BFD9-C20A645240A3Q34274925-152C670C-43A1-4CD5-AB62-EDB529D63CDDQ34570079-72EB4649-A671-4488-9DF6-237B5AB05509Q34636002-7ABCE41B-6D1C-4662-8358-7D9B301180CEQ34674197-C9B2B21E-2FCC-437F-ABFD-47B0D405A784Q34956830-DDCB8CFA-1BC5-459A-B6BE-620A6743F9C6Q34989039-9559312D-BDAD-46A4-BE88-CF5DC9F26958Q35205410-DD4246BE-C6D9-4398-B1D1-23ED0A8A3007Q35418973-6FA1670D-5F29-4B82-BE10-2F010765D7FBQ35541707-8E4256E6-777C-4309-A9F7-0B660E063226Q35584482-AB6235F8-1E57-41AD-AB06-2D522ED06D1FQ35604097-724C7937-85B1-4911-9140-427BEDB3C30AQ35813114-C0A56AA3-BC0D-41D4-994C-062B4BBC29D1Q35914787-D4515D30-D86B-4565-B5D0-7B71230E37B2Q36025388-2153B1F7-17D2-4BE0-83AB-EE1F3B12052F
P2860
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@en
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@nl
type
label
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@en
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@nl
prefLabel
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@en
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@nl
P2093
P50
P356
P1476
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@en
P2093
David Hong
Erik Rasmussen
Jeffrey L Evelhoch
Jeffrey M Silverman
Jonathan D Oliner
Lee S Rosen
Linnea Chap
Ngocdiep Le
Yu-Nien Sun
P304
P356
10.1200/JCO.2008.19.6683
P407
P577
2009-06-22T00:00:00Z